Back Pain News and Research

Latest Back Pain News and Research

SpinalMotion announces completion of enrollment in Kineflex lumbar artificial disc study

SpinalMotion, Inc., developer of the investigational Kineflex® lumbar and Kineflex®|C cervical disc implants for treating patients with degenerative disc disease (DDD), today reported that it has completed enrollment in an international clinical study evaluating the Kineflex lumbar artificial disc inserted via a minimally invasive lateral approach. The data from the study will be used to support regulatory submissions for international commercialization.

5 Oct 2010

Titan Spine to release new Endoskeleton TC system in first-quarter 2011

Titan Spine announced that it will begin full commercial release of its new Endoskeleton® TC system first quarter of 2011. The Endoskeleton® TC is an interbody fusion device for the cervical spine. The product received 510(k) clearance in July of this year and has been in limited market release since early August. The device has an acid etched titanium surface and is biomechanically designed to promote spinal fusion.

4 Oct 2010

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets.

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Sanofi-aventis announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana (cabazitaxel) Injection, was published in the October 2, 2010 print edition of The Lancet in an article titled "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

4 Oct 2010

BMC researchers receive grants to study effectiveness of integrative medicine in underserved patients

Two Boston Medical Center (BMC) researchers have each been awarded grants from the NIH National Center for Complementary and Alternative Medicine (NCCAM) to study the effectiveness of integrative medicine in underserved patients.

4 Oct 2010

Headaches, back pain and arthritis cost companies more than $61 billion per annum

Headaches, back pain, arthritis and other aches distract employees and cost companies more than $61 billion a year in lost productive time, according to a study published in the Journal of the American Medical Association.

1 Oct 2010

Wenzel Spine receives FDA marketing clearance for VariLift Expandable Interbody Fusion System

Wenzel Spine, Inc., a medical device company focused on offering less invasive, stand-alone alternatives to traditional spinal fusion, today announced they have received 510K clearance to market the VariLift Expandable Interbody Fusion System.

30 Sep 2010

Inefficiencies in treatment of chronic pain increases healthcare costs and prolongs patient suffering

A new report launched today in the European Parliament shows inefficiencies in the treatment of chronic pain result in increasing healthcare costs and prolonged patient suffering.

29 Sep 2010

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Afflicting countless people worldwide, chronic pain is a largely misunderstood and under-treated disease that forever alters the lives of more than 50 million Americans each year.

28 Sep 2010

Scientific data, evidence reject vertebroplasty procedure

As a patient safety best practice and endorsement of evidence-based medicine, the American Academy of Orthopaedic Surgeons Board of Directors approved and released a clinical practice guideline, which found a strong recommendation against a popular procedure called vertebroplasty as a way to treat fractures in the spine. Clinical practice guidelines are one avenue the Academy uses to ensure that patients receive high quality care.

28 Sep 2010

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control.

28 Sep 2010

Bayer’s new oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved a new oral contraceptive, Beyaz (drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).

28 Sep 2010

Technologic innovation — Telephones! — could save health system money

Health-coaching more patients over the phone could help save the system money according to a study published Wednesday in the New England Journal of Medicine and noticed by the Wall Street Journal's Health Blog. "Typically this kind of care management, as it's called, is offered to people who have trouble managing their chronic conditions or who are facing a big treatment decision — such as surgery or medical management for lower back pain.

24 Sep 2010

Mother’s miracle surgery for cancer - body cut in half

Janis Ollson, 31 became the first patient to survive a rare bone cancer which required her body to be cut in half. When she was pregnant with her second child doctors assumed her intense back pain was just a typical symptom of pregnancy. But soon she was diagnosed with a bone cancer called sarcoma that was untreatable by chemotherapy or radiation.

23 Sep 2010

FDA approves Gilenya capsules for reducing MS relapses

The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

22 Sep 2010

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics Pharmaceuticals, Inc. today announced the completion of the treatment phase of a 1,034-patient, one-year, open-label, international, phase 3 safety study of methylnaltrexone bromide subcutaneous injection in chronic, non-malignant pain patients with opioid-induced constipation (OIC).

22 Sep 2010

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.

20 Sep 2010

UCLA conference to provide information about latest developments to help enhance quality of life of seniors

While aging impacts everyday living in many ways, the latest technologies in the medical, consumer and lifestyle fields have the potential to help older adults live better for longer.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Back Pain News and Research

Latest Back Pain News and Research

SpinalMotion announces completion of enrollment in Kineflex lumbar artificial disc study

Titan Spine to release new Endoskeleton TC system in first-quarter 2011

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

BMC researchers receive grants to study effectiveness of integrative medicine in underserved patients

Headaches, back pain and arthritis cost companies more than $61 billion per annum

Wenzel Spine receives FDA marketing clearance for VariLift Expandable Interbody Fusion System

Inefficiencies in treatment of chronic pain increases healthcare costs and prolongs patient suffering

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

Scientific data, evidence reject vertebroplasty procedure

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Bayer’s new oral contraceptive receives FDA approval

Technologic innovation — Telephones! — could save health system money

Mother’s miracle surgery for cancer - body cut in half

FDA approves Gilenya capsules for reducing MS relapses

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Dapagliflozin added to glimepiride therapy reduces HbA1c in adult type 2 diabetes patients

UCLA conference to provide information about latest developments to help enhance quality of life of seniors

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Back Pain News and Research

Latest Back Pain News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in